Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP.

Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP.
复制标题

DOI:
10.1021/acs.jmedchem.2c00562
复制
发表时间:
2022-08-25
影响因子:
7.3
通讯作者:
Rais, Rana
Rais, Rana
中科院分区:
医学1区
文献类型:
--
作者:
Pal, Arindom;Gori, Sadakatali;Yoo, Seung-wan;Thomas, Ajit G.;Wu, Ying;Friedman, Jacob;Tenora, Lukas;Bhasin, Harshit;Alt, Jesse;Haughey, Norman;Slusher, Barbara S.;Rais, Rana

文献摘要

参考文献

被引文献

相似文献

细胞外囊泡(EV)可以携带病理货物,并在疾病进展中发挥积极作用。中性鞘磷脂酶-2(nSMase 2)是EV生物发生的关键调节因子,其抑制在多种疾病状态中显示出保护作用。2,6-二甲氧基-4-(5-苯基-4-噻吩-2-基-1H-咪唑-2-基)-苯酚(DPTIP)是迄今发现的最有效的(IC 50 =30 nM)nSMase 2抑制剂之一。然而,DPTIP表现出较差的口服药代动力学(PK),限制了其临床发展。为了克服DPTIP的PK限制,我们通过掩蔽其酚羟基来合成一系列前药。当口服给药时,具有2 ',6'-二乙基-1,4 '-联哌啶基-前体部分的最佳前药(P18)与DPTIP相比,显示出>4倍的血浆(AUC 0-t=1047 pmol.h/mL)和脑暴露(AUC 0-t=247 pmol.h/g);以及DPTIP半衰期的显著延长(2 h对约0.5 h)。在小鼠急性脑损伤模型中,从P18释放的DPTIP显著抑制IL-1β诱导的EV释放到血浆中并减弱nSMase 2活性。这些研究报告了具有临床转化潜力的DPTIP-前药的发现。
Extracellular vesicles (EVs) can carry pathological cargo and play an active role in disease progression. Neutral Sphingomyelinase-2 (nSMase2) is a critical regulator of EV biogenesis, and its inhibition has shown protective effects in multiple disease states. 2,6-Dimethoxy-4-(5-phenyl-4-thiophen-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) is one of the most potent (IC50=30 nM) inhibitor of nSMase2 discovered to-date. However, DPTIP exhibits poor oral pharmacokinetics (PK), limiting its clinical development. To overcome DPTIP’s PK limitations, we synthesized a series of prodrugs by masking its phenolic hydroxyl group. When administered orally, the best prodrug (P18) with a 2’,6’-diethyl-1,4’-bipiperidinyl-promoiety exhibited >4-fold higher plasma (AUC0-t=1047 pmol.h/mL) and brain exposures (AUC0-t=247 pmol.h/g) versus DPTIP; and a significant enhancement of DPTIP half-life (2 h vs. ~0.5 h). In a mouse model of acute brain injury, DPTIP released from P18 significantly inhibited IL-1β-induced EV release into plasma and attenuated nSMase2 activity. These studies report the discovery of a DPTIP-prodrug with potential for clinical translation.
DOI: 10.1038/s41598-020-73411-7
发表时间: 2020-09-30
期刊: Scientific reports
影响因子: 4.6
作者:
Burrello J;Biemmi V;Dei Cas M;Amongero M;Bolis S;Lazzarini E;Bollini S;Vassalli G;Paroni R;Barile L
通讯作者: Barile L
DOI: 10.1016/j.neurobiolaging.2014.02.012
发表时间: 2014-08
影响因子: 4.2
作者:
Dinkins MB;Dasgupta S;Wang G;Zhu G;Bieberich E
通讯作者: Bieberich E
DOI: 10.1002/jps.10083
发表时间: 2002-03-01
影响因子: 3.8
作者:
Hussain, AA;Al-Bayatti, AA;Hussain, MA
通讯作者: Hussain, MA
DOI: 10.1074/jbc.m117.793521
发表时间: 2017-07-14
影响因子: 4.8
作者:
Barclay, Robert A.;Schwab, Angela;Kashanchi, Fatah
通讯作者: Kashanchi, Fatah
DOI: 10.1002/glia.23708
发表时间: 2019-08-30
期刊: GLIA
影响因子: 6.2
作者:
Chaudhuri, Amrita Datta;Dasgheyb, Raha M.;Haughey, Norman J.
通讯作者: Haughey, Norman J.